SLC25A22 exerts oncogenic effects in colorectal cancer (Wong et al., 2016), gallbladder cancer (Du et al., 2019), and osteosarcoma cells (Chen and Wu, 2018), mainly through its transport of glutamate across the inner mitochondrial membrane to the mitochondrial matrix. This evidence concerns the gene SLC25A22 and osteosarcoma.